Abiomed (ABMD) Posts Q4 GAAP EPS of $2.24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Remains Bullish Toward AbioMed (ABMD) After Outstanding Quarter; PT to $88
May 6, 2015 10:03 AM EDTLeerink Partners maintained an Outperform rating on AbioMed, Inc. (NASDAQ: ABMD) and raises the price target to $88 (from$72) after an outstanding quarter. with accelerating Impella utilization trends, higher sales guidance, signs point to another great quarter.
Danielle Antalffy, an analyst from Leerink Partners said, "We believe ABMD's strong momentum is sustainable for at least the next few years as the company continues to penetrate the emergent and prophylactic (high risk PCI) patient... More
Jefferies Says That Abiomed (ABMD) Run is 'Just Getting Started'
May 6, 2015 9:31 AM EDTJefferies reiterates their Buy rating on Abiomed (NASDAQ: ABMD) and raise the price target to $83 (from $72) saying that the run is "just getting started". With a 30% revenue growth, and sales that are exceeding original estimates, ABMD guidance is going higher. Everything is finally all... More
